File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors

TitleEffectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors
Authors
Issue Date2005
PublisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJT
Citation
American Journal Of Transplantation, 2005, v. 5 n. 6, p. 1437-1445 How to Cite?
AbstractUse of hepatitis B surface antigen (HBsAg) positive donors for allogeneic hematopoietic stem cell transplantation (HSCT) causes serious hepatitis B virus (HBV)-related liver morbidity and mortality in the recipient. We compared the effectiveness of anti-HBV therapy in 29 recipients who underwent HSCT using HBsAg positive marrow (group I) against a historical control group of 25 patients who received HBsAg positive marrow without pre-HSCT prophylaxis (group II). Anti-HBV therapy consisted of lamivudine for HBsAg-positive donors and all recipients (n = 29) as well as HBV vaccination to all HBsAg-negative recipients (n = 10) before HSCT. After transplantation, HBV-related hepatitis was significantly higher in group II than group I recipients [12 of 25 recipients (48%) vs. 2 of 29 recipients (6.9%), p = 0.002] and in recipients whose donors had detectable serum HBV DNA by Digene Hybrid Capture II assay [8 of 14 recipients (57.1%) vs. 6 of 40 recipients (15.0%), p = 0.02]. Six recipients in group II and none in group I died of HBV-related hepatic failure (24.0% vs. 0%, p = 0.01). By multivariate Cox analysis, anti-HBV therapy effectively reduces post-HSCT HBV-related hepatitis (p = 0.01, adjusted hazards ratio 7.27, 95%CI 1.62-32.58). Our data support the use of prophylactic therapy in preventing HBV-related hepatitis after allogeneic HSCT from HBsAg-positive donor. Copyright © Blackwell Munksgaard 2005.
Persistent Identifierhttp://hdl.handle.net/10722/76776
ISSN
2015 Impact Factor: 5.669
2015 SCImago Journal Rankings: 2.792
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHui, CKen_HK
dc.contributor.authorLie, Aen_HK
dc.contributor.authorAu, WYen_HK
dc.contributor.authorMa, SYen_HK
dc.contributor.authorLeung, YHen_HK
dc.contributor.authorZhang, HYen_HK
dc.contributor.authorSun, Jen_HK
dc.contributor.authorCheung, WWWen_HK
dc.contributor.authorChim, CSen_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorLau, GKKen_HK
dc.date.accessioned2010-09-06T07:24:48Z-
dc.date.available2010-09-06T07:24:48Z-
dc.date.issued2005en_HK
dc.identifier.citationAmerican Journal Of Transplantation, 2005, v. 5 n. 6, p. 1437-1445en_HK
dc.identifier.issn1600-6135en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76776-
dc.description.abstractUse of hepatitis B surface antigen (HBsAg) positive donors for allogeneic hematopoietic stem cell transplantation (HSCT) causes serious hepatitis B virus (HBV)-related liver morbidity and mortality in the recipient. We compared the effectiveness of anti-HBV therapy in 29 recipients who underwent HSCT using HBsAg positive marrow (group I) against a historical control group of 25 patients who received HBsAg positive marrow without pre-HSCT prophylaxis (group II). Anti-HBV therapy consisted of lamivudine for HBsAg-positive donors and all recipients (n = 29) as well as HBV vaccination to all HBsAg-negative recipients (n = 10) before HSCT. After transplantation, HBV-related hepatitis was significantly higher in group II than group I recipients [12 of 25 recipients (48%) vs. 2 of 29 recipients (6.9%), p = 0.002] and in recipients whose donors had detectable serum HBV DNA by Digene Hybrid Capture II assay [8 of 14 recipients (57.1%) vs. 6 of 40 recipients (15.0%), p = 0.02]. Six recipients in group II and none in group I died of HBV-related hepatic failure (24.0% vs. 0%, p = 0.01). By multivariate Cox analysis, anti-HBV therapy effectively reduces post-HSCT HBV-related hepatitis (p = 0.01, adjusted hazards ratio 7.27, 95%CI 1.62-32.58). Our data support the use of prophylactic therapy in preventing HBV-related hepatitis after allogeneic HSCT from HBsAg-positive donor. Copyright © Blackwell Munksgaard 2005.en_HK
dc.languageengen_HK
dc.publisherBlackwell Munksgaard. The Journal's web site is located at http://www.blackwellpublishing.com/journals/AJTen_HK
dc.relation.ispartofAmerican Journal of Transplantationen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntibiotic Prophylaxisen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHematopoietic Stem Cell Transplantationen_HK
dc.subject.meshHepatitis B Surface Antigens - immunologyen_HK
dc.subject.meshHepatitis B virus - physiologyen_HK
dc.subject.meshHepatitis B, Chronic - drug therapy - immunologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshReverse Transcriptase Inhibitors - therapeutic useen_HK
dc.subject.meshTissue Donorsen_HK
dc.subject.meshTransplantation, Homologousen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleEffectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donorsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1600-6135&volume=5&spage=1437&epage=1445&date=2005&atitle=Effectiveness+of+Prophylactic+Anti-HBV+Therapy+in+Allogeneic+Hematopoietic+Stem+Cell+Transplantation+with+HBsAg+Positive+Donorsen_HK
dc.identifier.emailLeung, YH:ayhleung@hku.hken_HK
dc.identifier.emailChim, CS:jcschim@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.authorityLeung, YH=rp00265en_HK
dc.identifier.authorityChim, CS=rp00408en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1600-6143.2005.00887.xen_HK
dc.identifier.pmid15888052-
dc.identifier.scopuseid_2-s2.0-20544442183en_HK
dc.identifier.hkuros121076en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-20544442183&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume5en_HK
dc.identifier.issue6en_HK
dc.identifier.spage1437en_HK
dc.identifier.epage1445en_HK
dc.identifier.isiWOS:000229031400034-
dc.publisher.placeDenmarken_HK
dc.identifier.scopusauthoridHui, CK=7202876933en_HK
dc.identifier.scopusauthoridLie, A=24284842400en_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridMa, SY=7403725725en_HK
dc.identifier.scopusauthoridLeung, YH=7403012668en_HK
dc.identifier.scopusauthoridZhang, HY=8965962000en_HK
dc.identifier.scopusauthoridSun, J=7410369598en_HK
dc.identifier.scopusauthoridCheung, WWW=8615134400en_HK
dc.identifier.scopusauthoridChim, CS=7004597253en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK
dc.identifier.citeulike199139-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats